Merck Still Wants to "Grow Through Keytruda," Expects $70B in Revenue From New Programs by Mid-2030s
At the JP Morgan Healthcare Conference, the firm highlighted two antibody-drug conjugates among 10 programs that will fuel ...
The firm expects Phase III data for its investigational selective estrogen receptor degrader camizestrant and its CLDN18.2 ADC sonesitatug vedotin this year.
The firm is focused on helping pharma characterize response and resistance to their drugs, with the hope of getting a companion diagnostic approval.
The firm expects a first readout from an investigator-initiated trial of an in vivo CAR T-cell therapy in the second half of this year.
The firm is expecting a slew of key readouts for mRNA vaccines for treating cancer and rare diseases and is exploring vaccines for autoimmune conditions.
The partners will focus on treating Swiss patients with very rare diseases and then use the framework developed to establish similar pathways throughout Europe.
The FDA previously declined to approve UX111 citing CMC-related observations, but the firm is hopeful the agency will approve its new regulatory application.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback